NX Pharmagen
Louisville, US · Delaware corporation
Founders & leadership
FM
Fred MermelsteinNamed on SEC filing
RS
Robert SaundersNamed on SEC filing
BB
Brian BrohmanNamed on SEC filing
AE
Alan EzrinNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 2 rounds · 2020–2022
▶$590KraisedOct 2022 · 19 investors · BiotechnologyRule 506(b)
▶$590KraisedOct 2022 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan EzrinDirector
- Brian BrohmanExecutive Officer, Director
- Robert SaundersDirector
- Offering amount
- $1M
- Amount sold
- $590K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$486KraisedAug 2020 · 13 investors · Other Health CareRule 506(b)
▶$486KraisedAug 2020 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Fred MermelsteinDirector
- Robert SaundersDirector
- Brian BrohmanExecutive Officer, Director
- Alan EzrinDirector
- Offering amount
- $1M
- Amount sold
- $486K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has NX Pharmagen raised?
- NX Pharmagen has disclosed $1.1M raised across 2 rounds.
- Where is NX Pharmagen headquartered?
- NX Pharmagen is headquartered in Louisville, US.